Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced the appointment of Eran Kuratz as head of supply chain and business process administration for its wholly owned subsidiary, Scinai Biopharma Services Ltd. Kuratz brings over three decades of leadership and operational experience in the pharmaceutical, biotechnology, medical-device, and industrial sectors. He will be responsible for procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity, and cross-functional business processes.
This strategic hire comes as Scinai expands its contract development and manufacturing organization (CDMO) platform through the planned acquisition of Recipharm Israel, expected to close in the first quarter of 2026. The acquisition will add a second development and manufacturing site in Yavne, complementing Scinai's existing operations in Jerusalem. Together, these facilities will offer a comprehensive range of services, including biologics process development, aseptic manufacturing, sterile fill-and-finish, small-molecule active pharmaceutical ingredient development and synthesis, analytical-method development, and GMP manufacturing.
The appointment of Kuratz is pivotal for Scinai as it seeks to integrate the new capabilities and streamline operations across its expanded CDMO footprint. His expertise in supply chain management and business process optimization will be critical in ensuring seamless transitions and efficient operations, ultimately enhancing the company's ability to serve its clients in the biotech and pharmaceutical industries.
Scinai Immunotherapeutics is a biopharmaceutical company dedicated to developing innovative immunology therapies. The company's pipeline includes therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. In addition to its CDMO services, Scinai continues to advance its own drug development programs.
The move reflects Scinai's commitment to strengthening its position in the CDMO market, which is experiencing growing demand for specialized manufacturing services. By enhancing its operational capabilities and leadership team, Scinai aims to deliver high-quality services to its partners and maintain a competitive edge in the industry.
For more information about Scinai Immunotherapeutics and its services, visit the company's newsroom at https://ibn.fm/SCNI.
